Fig. 2: PG545 synergizes with rucaparib and olaparib to inhibit colony formation and promote apoptosis of OC cells.
From: PG545 sensitizes ovarian cancer cells to PARP inhibitors through modulation of RAD51-DEK interaction
A, B Percent Annexin V+ cells from Flow cytometry analysis of Annexin V+ cells in OVCAR5 treated with 1 µM PG545 alone and in combination with either 500 nM rucaparib or olaparib, respectively. C, F Heat map from the results of Colony formation assays CFAs in OVCAR5 and OVCAR8 cells treated with the indicated concentrations of PG545 alone or in combination with rucaparib and olaparib showed synergy with combination index (CI) values <1. (D, E and G, H, respectively) The straight line is the additive isobole with synergistic dose combinations labeled below the isobole for rucaparib and olaparib in OVCAR5 and OVCAR8 cells respectively. An average CI of 1 indicates an additive effect, CI < 1 a synergistic effect, and CI > 1 an antagonistic effect.
